Smiddy, William E <br/><br/>
Economic implications of current age-related macular degeneration treatments.  [electronic resource] 

 -  Ophthalmology  Mar 2009 
 - 481-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1549-4713 
<br/><br/><label>Standard No.: </label>10.1016/j.ophtha.2008.10.029  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--economics<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Combined Modality Therapy<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Glucocorticoids--economics<br/>Health Care Costs<br/>Humans<br/>Macular Degeneration--economics<br/>Models, Economic<br/>Photochemotherapy--economics<br/>Ranibizumab<br/>Triamcinolone Acetonide--economics<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vision Disorders--economics<br/>Visual Acuity